Excerpts from CGS-CIMB report

Analyst: ONG Khang Chuen, CFA

Higher ASPs on the cards
■ We reiterate our positive view on UG Healthcare Corp (UGHC) as we believe higher ASPs are on the cards given the surge in glove demand.

UG Healthcare 

Share price: 
$1.56

Target: 
$2.10

■ We now impute 20% ASP qoq growth for UGHC’s OBM gloves in 4QFY6/20F and 1QFY21F into our model. Our FY20-22F EPS is lifted by 9.2%-57.2%.

■ Despite the recent rally, we believe UGHC’s valuation remains attractive at 11.2x CY21F P/E.

Reiterate Add with a higher TP of S$2.10.


Quantum of ASP hike likely to be higher than expected
Our recent channel checks suggest that Malaysian-based glove makers have hiked their average selling prices (ASPs) at a faster rate than our forecasts.

OngKhangChuen"We forecast UGHC’s current ASPs to hold up till 1Q21, before a gradual normalisation of prices as higher industry supply kicks in.

"Our FY20-22F EPS is lifted by 9.2%-57.2% mainly to account for higher ASPs."

-- ONG Khang Chuen, CFA

For example, we gather that Supermax’s ASPs likely saw a c.35% qoq increase in the Apr-Jun 2020 quarter.

We believe this reflects the urgent demand for gloves, as daily new cases of Covid-19 worldwide continue to be on an uptrend.

We now impute a 20% ASP growth qoq for UGHC’s own brand manufacturing (OBM) gloves (which accounts for c.70% sales volume) in 4QFY6/20F and 1QFY21F into our model.

Forecasting record-breaking 2HFY20F results
UGHC is set to announce its 2HFY6/20F results by mid-Aug 2020.

We expect UGHC to record a sequentially stronger net profit of S$10.1m in 2HFY20F, a 11.9x jump on a hoh basis.

This will be mainly driven by:

1) higher ASPs,
2) lower raw material prices, and
3) cost savings from internal efficiency enhancements and better economies of scale.

Our forecasted EBITDA margins for 2HFY20F/FY21F stand at 19.0%/27.2%, at the lower-end of glove makers under our coverage.

Reiterate Add, with a higher TP of S$2.10
UGHC remains our preferred pick among the Singapore-listed rubber glove sector, due to its undemanding valuation (a c.60% discount to the Malaysia-listed glove sector average CY21F P/E of 29.3x) and OBM business model, which allows it to garner stronger ASP upside potential vs. its peers given the current strong surge in glove demand.

Our TP is lifted to S$2.10, still pegged to 15.0x CY21F P/E to reflect the current favourable operating environment for glove players.

Potential re-rating catalysts include further price hikes; downside risks include earlier ASP normalisation.


Full report here. 

You may also be interested in:


You have no rights to post comments

Counter NameLastChange
AEM Holdings1.8600.020
Best World2.5000.020
Boustead Singapore0.950-
Broadway Ind0.1480.003
China Aviation Oil (S)0.8700.005
China Sunsine0.4000.010
ComfortDelGro1.380-0.010
Delfi Limited0.875-
Food Empire1.110-0.010
Fortress Minerals0.295-0.015
Geo Energy Res0.3050.005
Hong Leong Finance2.4400.020
Hongkong Land (USD)3.5000.080
InnoTek0.5100.005
ISDN Holdings0.3050.005
ISOTeam0.0500.003
IX Biopharma0.0400.001
KSH Holdings0.2500.005
Leader Env0.049-
Ley Choon0.054-0.001
Marco Polo Marine0.067-0.001
Mermaid Maritime0.1380.003
Nordic Group0.305-
Oxley Holdings0.087-0.003
REX International0.1260.002
Riverstone0.930-
Southern Alliance Mining0.4850.005
Straco Corp.0.480-0.010
Sunpower Group0.220-0.010
The Trendlines0.063-
Totm Technologies0.0200.001
Uni-Asia Group0.810-
Wilmar Intl3.130-0.030
Yangzijiang Shipbldg1.740-0.010
 

We have 672 guests and no members online

rss_2 NextInsight - Latest News